v2.4.1.9
Segment reporting (Tables)
3 Months Ended
Mar. 31, 2015
Segment Reporting [Abstract]  
Summary of Segment Net Revenues, Segment Operating Income Loss and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes

The following is a summary of segment net revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:

 

 

 

Three months ended

 

 

 

March 31,

 

 

 

2015

 

 

2014

 

Segment net revenues:

 

 

 

 

 

 

 

 

U.S. dialysis and related lab services

 

 

 

 

 

 

 

 

Patient service revenues:

 

 

 

 

 

 

 

 

External sources

 

$

2,154,294

 

 

$

2,028,743

 

Intersegment revenues

 

 

11,856

 

 

 

7,832

 

Total dialysis and related lab services revenues

 

 

2,166,150

 

 

 

2,036,575

 

Less: Provision for uncollectible accounts

 

 

(97,477

)

 

 

(81,463

)

Net dialysis and related lab services patient service

   revenues

 

 

2,068,673

 

 

 

1,955,112

 

Other revenues(1)

 

 

3,184

 

 

 

3,154

 

Total net dialysis and related lab services revenues

 

 

2,071,857

 

 

 

1,958,266

 

HCP

 

 

 

 

 

 

 

 

HCP revenues:

 

 

 

 

 

 

 

 

Capitated revenues

 

 

832,472

 

 

 

771,542

 

Net patient service revenues

 

 

80,210

 

 

 

56,222

 

Other revenues(2)

 

 

15,053

 

 

 

12,523

 

Intersegment capitated and other revenues

 

 

37

 

 

 

152

 

Total revenues

 

 

927,772

 

 

 

840,439

 

Other—Ancillary services and strategic initiatives

 

 

 

 

 

 

 

 

Net patient service revenues

 

 

35,624

 

 

 

27,399

 

Capitated revenues

 

 

18,043

 

 

 

16,023

 

Other external sources

 

 

246,562

 

 

 

208,633

 

Intersegment revenues

 

 

4,942

 

 

 

4,819

 

Total ancillary services and strategic initiatives

   revenues

 

 

305,171

 

 

 

256,874

 

Total net segment revenues

 

 

3,304,800

 

 

 

3,055,579

 

Elimination of intersegment revenues

 

 

(16,835

)

 

 

(12,803

)

Consolidated net revenues

 

$

3,287,965

 

 

$

3,042,776

 

Segment operating margin (loss):

 

 

 

 

 

 

 

 

U.S. dialysis and related lab services

 

$

(104,489

)

 

$

386,700

 

HCP

 

 

60,294

 

 

 

53,953

 

Other—Ancillary services and strategic initiatives

 

 

(13,828

)

 

 

1,678

 

Total segment margin (loss)

 

 

(58,023

)

 

 

442,331

 

Reconciliation of segment operating margin to consolidated

   income from continuing operations before income taxes:

 

 

 

 

 

 

 

 

Corporate support costs

 

 

(6,133

)

 

 

(1,106

)

Consolidated operating (loss) income

 

 

(64,156

)

 

 

441,225

 

Debt expense

 

 

(97,392

)

 

 

(106,335

)

Other (loss) income

 

 

(533

)

 

 

1,698

 

Consolidated (loss) income from continuing

   operations before income taxes

 

$

(162,081

)

 

$

336,588

 

 

(1)

Includes management fees for providing management and administrative services to dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment.

(2)

Includes payments received for medical consulting services and management fees for providing management and administrative services to an unconsolidated joint venture that provides medical services in which the Company owns a 50% interest, as well as revenue related to the maintenance of existing physician networks.

Summary of Depreciation and Amortization Expense by Segment

Depreciation and amortization expense by segment is as follows:

 

 

 

Three months ended

 

 

 

March 31,

 

 

 

2015

 

 

2014

 

U.S. dialysis and related lab services.

 

$

104,993

 

 

$

96,443

 

HCP

 

 

43,279

 

 

 

41,737

 

Ancillary services and strategic initiatives

 

 

5,517

 

 

 

4,399

 

 

 

$

153,789

 

 

$

142,579

 

 

Summary of Assets by Segment

Summary of assets by segment is as follows:

 

 

 

March 31,

 

 

December 31,

 

 

 

2015

 

 

2014

 

Segment assets

 

 

 

 

 

 

 

 

U.S. dialysis and related lab services (including equity

   investments of $28,406 and $28,138, respectively)

 

$

11,352,546

 

 

$

10,959,096

 

HCP (including equity investments of $19,709 and $15,393,

   respectively)

 

 

6,313,981

 

 

 

6,285,984

 

Other—Ancillary services and strategic initiatives (including

   equity investments of $21,902 and $22,106, respectively)

 

 

700,136

 

 

 

697,635

 

Consolidated assets

 

$

18,366,663

 

 

$

17,942,715

 

 

Summary of Expenditures for Property and Equipment by Segment

Expenditures for property and equipment by segment is as follows:

 

 

 

Three months ended

 

 

 

March 31,

 

 

 

2015

 

 

2014

 

U.S. dialysis and related lab services.

 

$

105,395

 

 

$

113,230

 

HCP

 

 

5,034

 

 

 

4,502

 

Ancillary services and strategic initiatives

 

 

10,992

 

 

 

8,830

 

 

 

$

121,421

 

 

$

126,562